by HTLV | May 3, 2022 | Clinical Trials
Planned trial: Phase I trial of anti-chemokine receptor 4 Chimeric Antigen Receptor cells (CCR4-CARs) for the treatment of CCR4 expressing T-cell malignancies
by HTLV | May 3, 2022 | Clinical Trials
Ongoing clinical trials at NCI that are exclusive to or include patients with ATL: Investigation of the Human Immune Response in Normal Subjects and Patients With Disorders of the Immune System and Cancer...
by HTLV | May 3, 2022 | Clinical Trials
Ongoing clinical trials at NCI that are exclusive to or include patients with ATL: Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia (ATL)...
by HTLV | May 3, 2022 | Clinical Trials
Planned trial: Recombinant Human IL-15 (rhIL-15) and Mogamulizumab for Patients with Refractory or Relapsed Adult T-Cell Leukemia and Mycosis Fungoides/Sézary...
by HTLV | May 3, 2022 | Clinical Trials
Ongoing clinical trials at NCI that are exclusive to or include patients with ATL: Ruxolitinib for Adult T-cell Leukemia (https://clinicaltrials.gov/ct2/show/NCT01712659)
